SCHEMBL6030161

SCHEMBL6030161

COC(=O)C(Cc1ccccc1)NC(=O)c1ccc(-c2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.77
RAB9A P51151 1/20 0.77
PPARG P37231 1/20 0.64
GPR132 Q9UNW8 2/20 0.60
ERAP2 Q6P179 1/20 0.60
LNPEP Q9UIQ6 1/20 0.60
ALDH1A1 P00352 2/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
GLA P06280 1/20 0.56
PTPN1 P18031 1/20 0.55
YAP1 P46937 2/20 0.55
CTSB P07858 1/20 0.55
CTSS P25774 1/20 0.55
CTSK P43235 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LTA4H P09960 1/20 0.55
KLKB1 P03952 1/20 0.54
GPR34 Q9UPC5 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1122834 0.99 GAA (0.75) GAARAB9APPARGGPR132ERAP2
SCHEMBL1123055 0.95 GAA (0.80) GAARAB9APPARGGPR132ERAP2
SCHEMBL1122925 0.92 GAA (0.75) GAARAB9APPARGGPR132ERAP2
SCHEMBL1123370 0.91 GAA (0.73) GAARAB9APPARGGPR132ERAP2
SCHEMBL6029421 0.91 GAA (0.67) GAARAB9APPARGGPR132ERAP2
SCHEMBL1123028 0.89 GPR132 (0.71) GAARAB9APPARGGPR132ERAP2
SCHEMBL6029880 0.89 GPR132 (0.73) GAARAB9APPARGGPR132PTPN1
SCHEMBL1123382 0.89 GAA (0.71) GAARAB9APPARGGPR132ERAP2
SCHEMBL1123147 0.89 GAA (0.71) GAARAB9APPARGGPR132ERAP2
SCHEMBL27638047 0.89 RAB9A (0.74) GAARAB9APPARGGPR132ERAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060247260-A1 Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists BAYER HEALTHCARE AG (DE) 2006-11-02 US disclosed
EP-1594846-A1 BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS Bayer HealthCare AG (DE) 2005-11-16 EP disclosed
WO-2004069805-A1 BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS BAYER HEALTHCARE AG (DE) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247260-A1 Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists HRH2, BPHL, HRH1 GAA 3163/4885RAB9A 3403/4885PPARG 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.